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Objective: To evaluate a new pharmacological activity/effect of linolenic acid (a- and g-
form) and conjugated-linoleic acid (CLA) causing antibacterial activity against Myco-
bacterium tuberculosis (Mtb).
Methods: The anti-Mtb activity/effect of linolenic acid and CLA were determined using
different anti-Mtb indicator methods such as resazurin microtiter assay (REMA) and
MGIT 960 system assay. The Mtb was incubated with various concentrations
(12.5−200 mg/mL) of the compounds and anti-Mtb ﬁrst-line drugs for 5 d in the REMA,
and for 3 wk in MGIT 960 system assay.
Results: Linolenic acid and CLA obviously indicated their anti-Mtb activity/effect by
strongly inhibiting the growth/proliferation of Mtb in a dose-dependent manner in the
REMA and the MGIT 960 system assay. Interestingly, linolenic acid and CLA consis-
tently induced anti-Mtb activity/effect by effectively inhibiting the growth/proliferation of
Mtb in MGIT 960 system for 21 d with a single treatment, and their minimum inhibitory
concentrations were measured as 200 mg/mL respectively.
Conclusions: These results demonstrate that linolenic acid and CLA not only have
effective anti-Mtb activity/properties, but also induce the selective-anti-Mtb effects by
strongly inhibiting and blocking the growth/proliferation of Mtb through a new phar-
macological activity/action. Therefore, this study provides novel perspectives for the
effective use of them and the potential that can be used as potent anti-Mtb candidate
drugs, as well as suggests the advantage of reducing the cost and/or time for developing a
new/substantive drug by effectively repurposing the existing drugs or compounds as one
of new strategies for the global challenge of tuberculosis.1. Introduction
The rapid emergence of tuberculosis (TB) is still causing a
serious global challenge and difﬁculty including drug-resistant TB
despite various global efforts such as hygiene education,environment improvement, and drug development. Mycobacte-
rium tuberculosis (Mtb) is a major infectious factor causing the
highest humanmortality through the co-infection with HIV/AIDS
as one of themost dangerous infectious bacteria globally. In 2013,
9.0 million people were estimated as new TB, 1.5 million died
from the disease, and 360000 of them were HIV-positive. In
addition, 1.1 million of the 9 million people diagnosed as new TB
cases in 2013 were HIV-positive. Recently, TB cases co-infected
withHIV/AIDS indicated the highest infectious rate in theAfrican
region comparedwith the other countries, particularly, in southern
Africa. Furthermore, most of the estimated TB cases in 2013
occurred in Asia (56%) and the African region (29%), and the
three countries of the largest number of TB cases were India (2.0rticle under the CC BY-NC-ND license (http://
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(340000–880000) [1,2]. For these reasons, various studies for the
treatment and/or the inhibition of TB that induces drug-resistance
to existing agents have been carried out in the drug discovery ﬁeld
worldwide. Although various anti-TB drugs (from ﬁrst-line drugs
to third-line drugs) were developed for the treatment of TB pa-
tients, they have showed the limit in reducing the current TB pa-
tients. Recently, compounds such as PA 824, SQ 109,
bedaquiline, and linezolid repurposed through chemical remod-
eling of the existing drugs as well as new compounds such as
Q203, TMC 207, pyridomycin, and thiophenes are being tested in
Phase I or Phase III trials as novel anti-TB drugs [1,3–7]. Until
recently, in spite of the discovery of new targets and/or drugs
for treating TB, the rapid emergence of TB, and multi-drug-
resistant TB (MDR-TB) or extensively drug-resistant TB has
still caused serious concerns in the public health ﬁeld worldwide.
For these reasons, various studies for developing the effective
anti-TB drugs with novel mechanisms of action, low cytotoxicity
and safety are urgently needed to block and/or to inhibit the TB. In
this aspect, this studywas carried out to evaluate anti-Mtb activity/
effect/ability of linolenic acid (a- and g-form) and conjugated-
linoleic acid (CLA) that effectively act as bioactive substance,
and to identify the potential for developing them as novel anti-
tubercular drugs.
2. Materials and methods
2.1. Materials
Various materials used in this study, rifampicin, isoniazid,
linolenic acid (a- and g-form), CLA [conjugated(9Z,11E)-
linoleic acid, conjugated(9E,11E)-linoleic acid, and
conjugated(10E,12Z)-linoleic acid], resazurin powder and
DMSO, were purchased from Sigma–Aldrich Chemical, Co.,
Ltd. (St, Louis, MO, USA), and MGIT™ 960 system indicator
7 mL growth media tubes with BACTEC™ MGIT™ 960 sup-
plement kit were purchased from Becton–Dickinson and Com-
pany (Sparks, MD, USA). All other chemicals and reagents were
purchased from Merck Chemical Co., Ltd. (Darmstadt, Ger-
many) and Sigma–Aldrich Chemical Co., Ltd. (St. Louis, MO,
USA).
2.2. Preparation of anti-Mtb drugs
The anti-Mtb ﬁrst-line drug, isoniazid, was dissolved in
sterile distilled water, and rifampicin was dissolved in DMSO, to
a concentration of 50 mg/mL according to the manufacturer's
instruction. The anti-Mtb ﬁrst-line drugs were used as reference
standard drugs. All compounds were ﬁltered using 0.2 mm
membrane syringe ﬁlter (Roshi Kaisha, Ltd., Tokyo, Japan)
before use and stored at −80 C deep-freezer until use.
2.3. Preparation and growth conditions of Mtb
Mtb H37RV (ATCC 27294) used in this study was pur-
chased from American Type Culture Collection (Manassas,
VA, USA). Mtb H37RV was grown in Middlebrook 7H9 broth
(Difco Laboratories, Detroit, MI, USA) supplemented with
10% (V/V) oleic acid/albumin/dextrose/catalase enrichment
(Becton–Dickinson and Company, Sparks, MD, USA) and0.05% (v/v) Tween 80 (Sigma–Aldrich Chemical, St, Louis,
MO, USA) to the log phase at 37 C for 4–5 wk on shaking
incubation of 100 rpm.
2.4. Drug susceptibility testing of Mtb
The in vitro anti-Mtb activity of linolenic acid (a- and
g-form) and CLA [conjugated(9Z,11E)-linoleic acid,
conjugated(9E,11E)-linoleic acid, and conjugated(10E,12Z)-
linoleic acid] against Mtb was conﬁrmed by resazurin micro-
titer assay (REMA) using a 96-well micro-plate. Brieﬂy, Mtb
was grown in fresh Middlebrook 7H9 broth supplemented with
10% (v/v) oleic acid/albumin/dextrose/catalase enrichment and
0.05% (v/v) Tween 80 until the culture reached a turbidity
equal to that of 1.0 McFarland standard (3.0 × 108 CFU/mL) at
37 C. The bacteria were adjusted to a density of 2 × 106 CFU/
mL in fresh culture broth. Finally, the bacterial suspensions
were inoculated into all wells of a 96 well microtiter plate
containing ﬁnal concentrations (12.5−200 mg/mL) of linolenic
acid (a- and g-form), CLA [conjugated(9Z,11E)-linoleic acid,
conjugated(9E,11E)-linoleic acid, and conjugated(10E,12Z)-
linoleic acid] and anti-TB ﬁrst-line drugs (1.25−5 mg/mL),
and Mtb growth controls containing no anti-Mtb ﬁrst-line drugs
and blank controls without inoculation were also included. The
96 well-plates, covered with lids, placed in a plastic bag, were
incubated at 37 C for 5 d. After incubation, 20 mL of freshly
prepared 0.05% (w/v) resazurin solution was added to all wells
of a 96 well microtiter plate, and the plates were re-incubated at
37 C for 36 h. A change in color from blue to pink indicating
bacterial growth was observed after 36 h of incubation. The
minimum inhibitory concentration (MIC) was expressed as the
lowest concentration of the drug that inhibited Mtb growth or
prevented change in color of the resazurin from blue to pink
based on a REMA.
2.5. Evaluation of drug susceptibility of Mtb by MGIT
960 system assay
To evaluate anti-Mtb effects of linolenic acid (a- and g-form)
and CLA [conjugated(9Z,11E)-linoleic acid, conjugated(9E,11E)-
linoleic acid, and conjugated(10E,12Z)-linoleic acid] against the
growth/proliferation of Mtb, the drug susceptibility testing of the
strain was performed using the BACTEC™ MGIT 960 system
(Becton Dickinson and Company, Sparks, MD, USA.). In brief,
100 mL of a suspension of Mtb culture, adjusted to 9.6 × 106 CFU/
mL, was inoculated in an MGIT growth media tube with BAC-
TEC™ MGIT 960 growth supplement (Becton Dickinson and
Company), which were incubated with different concentrations
(12.5−200 mg/mL) of the tested compounds and anti-Mtb ﬁrst-line
drugs (10 mg/mL), and Mtb growth controls containing no anti-
Mtb ﬁrst-line drugs were also included. They were incubated
into the BACTEC™ MGIT 960 system device for 3 wk for
determination of Mtb drug susceptibility.
2.6. Statistical analysis
All results were expressed as mean ± standard deviation of
three independent experiments. Statistical analysis of the data
was performed using the Student's t-test and one-way analysis of
variance.
Table 2
MICs of linolenic acid (a- and g-form) and CLA against the growth/
proliferation of Mtb determined by different anti-Mtb assays.
Tested compounds MIC (mg/mL) of the
compounds determined by
different anti-Mtb assays
REMA
(incubation
days: 5)
MGIT 960
system
(incubation
days: 21)
a-Linolenic acid 75 200
g-Linolenic acid 75 200
CLA Conjugated(9E,11E)-linoleic acid 100 200
Conjugated(9Z,11E)-linoleic acid 100 200
Conjugated(10E,12Z)-linoleic acid 100 200
The anti-Mtb activity/effect of the compounds was measured by the
REMA and the MGIT 960 system assay. Mtb H37Rv was incubated
with different concentrations (12.5−200 mg/mL) of the compounds at
37 C, and its susceptibility was conﬁrmed by different anti-Mtb indi-
cator assays. The results of the REMA and the MGIT 960 system assay
were evaluated after 5 d and 21 d of incubation, respectively.
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3.1. Evaluation of anti-Mtb activity of the compounds
against Mtb
The anti-Mtb activity of linolenic acid (a- and g-form) and
CLA [conjugated(9Z,11E)-linoleic acid, conjugated(9E,11E)-
linoleic acid, and conjugated(10E,12Z)-linoleic acid] were
evaluated using the REMA. After the bacteria were incubated
with various concentrations (12.5−200 mg/mL) of the com-
pounds and anti-Mtb ﬁrst-line drugs (rifampicin and isoniazid)
for 5 d, the growth/proliferation of Mtb were markedly inhibited
in a concentration-dependent manner (Table 1), and the MIC
values of linolenic acid (a- and g-form) and CLA against the
viability of Mtb were determined as 75 mg/mL and 100 mg/mL,
respectively (Table 2). Furthermore, all the compounds
demonstrated their Mtb-inhibitory effects as well as anti-Mtb
activity through the bacterial color change observed in the
REMA. In the REMA, the superiority among the compounds
regarding anti-Mtb activity/effect was conﬁrmed that linolenic
acid (a- and g-form) was more effective compared with the
CLA. These results demonstrate that the compounds not only
induce anti-Mtb activity by strongly inhibiting the growth/pro-
liferation of Mtb, but also have the potential that can be devel-
oped as potent anti-Mtb agents through their new
pharmacological function/action.
3.2. Anti-Mtb effects of the compounds against the
growth/proliferation of Mtb
The anti-Mtb effects of the compounds against Mtb were
further evaluated using the MGIT 960 system assay. The bac-
teria were incubated with various concentrations (12.5−200 mg/
mL) of the compounds and anti-Mtb ﬁrst-line drugs (10 mg/mL)
in an MGIT growth media tube of the BACTEC™ MGIT 960
system device for drug susceptibility testing for 3 wk, and their
growth units were markedly inhibited in a concentration-
dependent manner. Particularly, when Mtb was incubated withTable 1
Anti-Mtb activity of linolenic acid (a- and g-form) and CLA against Mtb gr
Tested compounds Structure
a-Linolenic acid
g-Linolenic acid
Conjugated(9E,11E)-linoleic acid
Conjugated(9Z,11E)-linoleic acid
Conjugated(10E,12Z)-linoleic acid
The anti-Mtb activity of the compounds against the growth/proliferation of M
with different concentrations (12.5−200 mg/mL) of the compounds at 37 C f
sign shows 60%–75% inhibitory rates of the compounds against the growth100 mg/mL of the CLA, their growth units were detected at
about 8.3 d, whereas 100 mg/mL of linolenic acid (a- and g-
form) strongly inhibited the growth/proliferation of Mtb
compared with the CLA, and the growth unit of Mtb was
detected at 9.3 and 10.3 d, respectively (Figure 1). Furthermore,
when Mtb was incubated with all the tested compounds (200 mg/
mL), their growth units were not detected at 21 d. In this MGIT
960 system assay, linolenic acid (a- and g-form) and CLA
effectively inhibited the growth/proliferation of Mtb for 3 wk
with a single treatment, which showed clearly that these com-
pounds induced similar inhibitory effects against the growth/
proliferation of Mtb. These results demonstrate that the com-
pounds induce anti-Mtb activity/effect causing the inactivation
of Mtb by effectively blocking or consistently inhibiting the
growth/proliferation of Mtb, as well as have unique anti-
mycobacterial properties that induce anti-Mtb activity in a
concentration-dependent manner.owth/proliferation determined by the REMA assay.
Mol. weight (g/M) Concentrations (mg/mL)
200 100 50 25
278.43 + + ± −
278.43 + + ± −
280.45 + + ± −
280.45 + + ± −
280.45 + + ± −
tb H37Rv was measured using the REMA assay. The Mtb was incubated
or 5 d. The ‘+’ sign indicates anti-Mtb activity of the compounds, and ‘±’
/proliferation of Mtb.
Figure 1. Anti-Mtb activity/effect of linolenic acid (a- and g-form) and
CLA measured using the MGIT 960 system assay.
The Mtb was incubated with different concentrations (12.5−200 mg/mL) of
the compounds in the MGIT 960 system device at 37 C for 3 wk.
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The recent infectious pathogens have enhanced their infec-
tivity and viability through genetic mutation or adaptability to
environmental variation, which affects the treatment or preven-
tion of the disease as well as the novel drug discovery and
development. Recently serious infectious diseases such as
MERS, SARS, Inﬂuenza and Ebola have been occurred in
various countries worldwide, particularly, in Asia, Middle East
and Africa. These diseases have typically caused more serious
risk to young children whose immune function is low and the
elderly who have other underlying diseases compared with
normal adults. In these aspects, TB is a contagious/infectious
disease to cause infection through droplets, which has caused
comparatively high prevalence and mortality rates worldwide. In
addition, TB is the most dangerous factor among various in-
fectious diseases, which accounted for the second leading cause
of death among infectious diseases of the world's population in
2013 and 2014 [1,2]. In particular, the increase of HIV-co-
infection and the rapid appearance of MDR-TB strains
strongly suggest an urgent need to develop effective/safe drugs
for consistently treating TB as well as induce serious concerns
regarding drug-resistance in the public health ﬁelds. Recently, in
spite of various efforts to discover new anti-Mtb drugs, the
development for effective/safe anti-TB drugs has been still faced
with a global difﬁculty, including the cost & time and the
indifference of global pharmaceutical companies. Until recently,
novel antibiotics derived from diverse biological resources and
synthetic compounds have been developed to treat infectious
diseases or to inhibit pathogenic microorganisms. However, the
overuse of antibiotics and antibacterial drugs has rapidly
increased the incidence of multi-drug-resistant bacteria, so that
many medical doctors compared with the past were confronted
with more difﬁculty to treat patients with serious bacterial in-
fections such as MDR-TB and extensively drug-resistant TB. In
addition, the current anti-TB drugs have been causing serious
side effects such as hepatotoxicity, ototoxicity, and nephrotox-
icity. For these reasons, as one of feasible solutions for over-
coming limitations of the drug's side effects, a number of
researches regarding anti-Mtb drugs were reported from active
substances derived from diverse medicinal plants and biological
resources, and some of natural products have been studied or
developed as potent candidate substances for treating TB [8–12].
However, despite various efforts for developing novel anti-TBdrugs, effective/safe next-generation anti-Mtb agents that can
be used as a potential anti-TB drug, the extracts, natural prod-
ucts, semi-synthetic compounds and/or biomedicine, have not
yet been reported or released in pharmaceutical market.
Recently, innovative and creative alternatives for developing
effective/safe drugs through substantive solutions between sci-
entists and pharmaceuticals are being required globally.
In this aspect, the new pharmacological activity/effect of
existing drugs/compounds used for treating different diseases
can provide the advantages of both the safety and efﬁcacy
compared with newly developed drugs, which may be used or
utilized as one of effective strategies for developing novel drugs
and as one of feasible alternatives for developing effective/safe
next-generation drugs. Moreover, the compounds derived from
the repurposing of existing drugs may increase the potential for
developing new-next-generation drugs as a useful resource for
developing new substances in a medical ﬁeld. For these reasons,
this study was focused on major points for the discovery of new
candidate substances as one of various strategies for developing
anti-Mtb drugs, which were the minimization of side effects, the
safety of drugs, and the ﬁnding of novel pharmacological ac-
tivity/effect/function/action of existing drugs or known com-
pounds. In these perspectives, CLA and linolenic acid (a- and g-
form) are being used as adjuvant for both medical use and
healthcare as bioactive substances derived from various bio-
logical resources, including medicinal plants and marine re-
sources. Recently, new pharmacological activity/effect/actions
of CLA and linolenic acid (a- and g-form) have been variously
reported as follows: 1) Anti-adipogenic effect of a-linolenic acid
through AMP-activated protein kinase [13], 2) g-linolenic acid
increases the therapeutic efﬁcacy of irradiation in the treatment
of gliomas [14], 3) The modulatory effects of CLA against
both obesity and inﬂammatory bowel disease through
peroxisome proliferator-activated receptor gamma pathway
[15], 4) a-linolenic acid protects the heart from myocardial
ﬁbrosis and cardiac injury in the rat [16], 5) Anti-allergic effect
of a-linolenic acid in the gut of murine food allergy model [17],
6) The effect of omega-3 polyunsaturated fatty acid including a-
linolenic acid in treating patients with non-alcoholic steatohe-
patitis [18].
Taken together, these studies indicate substantial and sig-
niﬁcant evidence that linolenic acid (a- and g-form) and CLA
have not only various pharmacological activities/effects/actions
in both ‘in vitro’ and ‘in vivo’ but also the potential that can be
used as therapeutic agents. However, in spite of the pharmaco-
logical activities/effects/actions of them provided through these
studies, their anti-TB activity/effects against Mtb have not yet
been reported in both ‘in vitro’ and ‘in vivo’. In these aspects,
this study has begun from hypothesis that linolenic acid (a- and
g-form) and CLA may effectively inhibit or interrupt and
modulate the growth/proliferation of Mtb causing TB, which can
improve the safety and increase or induce the minimization of
the side effects that are caused by drug treatment. As mentioned
above, the results of this study showed anti-tubercular activity/
effect/ability of CLA and linolenic acid (a- and g-form) by
strongly inhibiting or blocking the growth/proliferation of Mtb
through their novel pharmacological activity/properties. Partic-
ularly, anti-Mtb activity/effect of linolenic acid (a- and g-form)
was effectively demonstrated through the selective Mtb
susceptibility-indicator assays such as the REMA and MGIT
960 system assay. All the tested compounds consistently indi-
cated anti-Mtb activity/effect by strongly inhibiting or blocking
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(200 mg/mL) in MGIT 960 system assay. In addition, the dif-
ferences in anti-Mtb activity/effect of them were obviously
conﬁrmed in the MGIT 960 system assay and the REMA assay;
Linolenic acid (g-form) more effectively inhibited the growth/
proliferation of Mtb compared with those of linolenic acid (a-
form) and CLA. The important aspect that can be considered at
this point is that all the tested compounds are unsaturated fatty
acid. This suggests that when the compounds are bound with
Mtb in the growth stages of Mtb, chemical-binding effects be-
tween the compound and the bacteria can be increased owing to
its chemical properties such as chemical afﬁnity, absorbability,
melting point, and liposolubility. Furthermore, it implies that the
biochemical reactions and/or functions of the cell wall of Mtb
may be blocked or inhibited by the binding of the compounds,
and suggests that a cascading intracellular signaling-pathway of
replication as well as cell cycle-key proteins in cytoplasm may
be deactivated by the compound at check points that accelerate
the growth/proliferation of Mtb.
In summary, linolenic acid (a- and g-form) and CLA
strongly inhibited the growth/proliferation of Mtb that can
induce TB in those with weakened immune systems through
their novel pharmacological activity/effect/function, and their
anti-Mtb activity/effect and action were demonstrated through
different anti-Mtb indicator assays such as the MGIT 960 system
assay and the REMA. In particular, linolenic acid (g-form) more
effectively inhibited the growth/proliferation of Mtb compared
with other compounds used in this study. These results showed
not only the potential for the effective use of linolenic acid (a-
and g-form) and CLA as one of feasible solutions for inhibiting
or blocking TB that causes a serious threat in public health
ﬁelds, but also a new pharmacological function/action con-
cerning anti-Mtb activity/effect of them against Mtb. Therefore,
this study provides signiﬁcant results that linolenic acid (a- and
g-form) and CLA can be effectively used or utilized as potent
candidate drugs for developing new anti-Mtb drugs of the
effective/safe next-generation in the near future. In addition, this
study suggests that the compounds have the potential which may
decrease the cost and/or time in clinical trials through their
repurposing.
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